Clinical Trial Update: Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial update for Prolgolimab 250 mg every 3 weeks in unresectable or metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Prolgolimab (prolgolimab)

Snippet

Sponsor: Biocad | Conditions: Unresectable or Metastatic Melanoma | Phase 3 | Status: UNKNOWN